Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
SOMERSET, N.J., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell...
immunotherapy
Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024
Media Release Oral presentation will detail results from the randomized TACTI-003 Phase IIb trial in first line head & neck...
IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody
Media Release IMP761 is designed to enhance the “brake” function of LAG-3 on T cells to restore balance to the...
Colorectal Cancer and Gut Health: Insights from Dr. Richard Birkett
BOSTON, MA / ACCESSWIRE / August 13, 2024 / Colorectal cancer, a serious condition affecting the colon or rectum, is...
U.S. News & World Report Ranks John Theurer Cancer Center as the #1 Cancer Program in NJ and the Only Top 50 Cancer Program in the State
Regional Cancer Care Associates is pleased to announce the recognition of John Theurer Cancer Center as the #1 Cancer Program...
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin...
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with...
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Announced positive survival data from the phase 2 randomized controlled clinical trial of CAN-2409 in borderline resectable pancreatic cancerPresented positive...
PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage...
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
SEATTLE, WA / ACCESSWIRE / August 8, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing...
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC...
PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage...
Immutep to Participate in Upcoming Investor Conferences
SYDNEY, AUSTRALIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology...
Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a...
Y-mAbs to Participate in Upcoming Investor Conferences in August
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
Nammi Therapeutics, Inc. Completes Series B Round with Investment from MMRF’s Myeloma Investment Fund; Advances Clinical Development of Lead Program, QXL138AM
LOS ANGELES, Aug. 6, 2024 /PRNewswire/ -- Nammi Therapeutics, Inc. (Nammi) announces a $1M investment commitment by the Myeloma Investment...
Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion...
TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call
Call Scheduled for Thursday, August 15, 2024, at 9:00 a.m. ETDENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company...
Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet...